Katy J L Bell1,2, Yachna Mehta3, Robin M Turner4, Rachael L Morton5, Mbathio Dieng1,6, Robyn Saw7,8,9, Pascale Guitera7,10,11, Kirsten McCaffery1, Donald Low12, Cynthia Low12, Marisa Jenkins1, Les Irwig1, Angela C Webster1. 1. The School of Public Health, The University of Sydney, Sydney, New South Wales, Australia. 2. Center for Evidence Based Practice, Bond University, Gold Coast, Queensland, Australia. 3. Australia New Zealand Melanoma Trials Group, Melanoma Institute Australia, Sydney, New South Wales, Australia. 4. School of Public Health and Community Medicine, University of New South Wales, Sydney, New South Wales, Australia. 5. NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia. 6. Macquarie University, Sydney, New South Wales, Australia. 7. Melanoma Institute Australia, Sydney, New South Wales, Australia. 8. Discipline of Surgery, The University of Sydney, Sydney, New South Wales, Australia. 9. Division of Surgery, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia. 10. Discipline of Dermatology, The University of Sydney, Sydney, New South Wales, Australia. 11. The Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia. 12. Cancer Voices NSW, Sydney, New South Wales, Australia.
Abstract
OBJECTIVE: To estimate the amount of fear of new or recurrent melanoma among people treated for localised melanoma in an Australian specialist centre. METHODS: We randomly selected 400 potential participants from all those treated for localised melanoma at the Melanoma Institute Australia during 2014 (n = 902). They were asked to complete an adapted version of the Fear of Cancer Recurrence Inventory (FCRI). We calculated summary statistics for demographics, clinical variables and total FCRI and subscale scores. RESULTS: Two hundred fifteen people (54%) completed the FCRI questionnaire. The overall mean severity subscale score was 15.0 (95% CI 14.0-16.1). A high proportion of participants had scores above a proposed threshold to screen for clinical fear of cancer recurrence (77% and 63% of participants with and without new or recurrent melanoma had severity subscale scores ≥13). Most participants also had scores above a threshold found to have high specificity for clinical fear of cancer recurrence (65% and 48% of participants with and without new or recurrent melanoma had severity subscale scores ≥16). The severity subscale appeared to discriminate well between groups with differing levels of risk of new or recurrent melanoma. CONCLUSIONS: There is a substantial amount of fear of new or recurrent melanoma among this population, despite most having a very good prognosis.
OBJECTIVE: To estimate the amount of fear of new or recurrent melanoma among people treated for localised melanoma in an Australian specialist centre. METHODS: We randomly selected 400 potential participants from all those treated for localised melanoma at the Melanoma Institute Australia during 2014 (n = 902). They were asked to complete an adapted version of the Fear of Cancer Recurrence Inventory (FCRI). We calculated summary statistics for demographics, clinical variables and total FCRI and subscale scores. RESULTS: Two hundred fifteen people (54%) completed the FCRI questionnaire. The overall mean severity subscale score was 15.0 (95% CI 14.0-16.1). A high proportion of participants had scores above a proposed threshold to screen for clinical fear of cancer recurrence (77% and 63% of participants with and without new or recurrent melanoma had severity subscale scores ≥13). Most participants also had scores above a threshold found to have high specificity for clinical fear of cancer recurrence (65% and 48% of participants with and without new or recurrent melanoma had severity subscale scores ≥16). The severity subscale appeared to discriminate well between groups with differing levels of risk of new or recurrent melanoma. CONCLUSIONS: There is a substantial amount of fear of new or recurrent melanoma among this population, despite most having a very good prognosis.
Authors: Wei-Yin Lim; Rachael L Morton; Robin M Turner; Marisa C Jenkins; Pascale Guitera; Les Irwig; Angela C Webster; Mbathio Dieng; Robyn P M Saw; Donald Low; Cynthia Low; Katy J L Bell Journal: JAMA Dermatol Date: 2018-04-01 Impact factor: 10.282
Authors: Deonna M Ackermann; Mbathio Dieng; Ellie Medcalf; Marisa C Jenkins; Cathelijne H van Kemenade; Monika Janda; Robin M Turner; Anne E Cust; Rachael L Morton; Les Irwig; Pascale Guitera; H Peter Soyer; Victoria Mar; Jolyn K Hersch; Donald Low; Cynthia Low; Robyn P M Saw; Richard A Scolyer; Dorothy Drabarek; David Espinoza; Anthony Azzi; Alister M Lilleyman; Amelia K Smit; Peter Murchie; John F Thompson; Katy J L Bell Journal: JAMA Dermatol Date: 2022-01-01 Impact factor: 11.816
Authors: Wei-Yin Lim; Robin M Turner; Rachael L Morton; Marisa C Jenkins; Les Irwig; Angela C Webster; Mbathio Dieng; Robyn P M Saw; Pascale Guitera; Donald Low; Cynthia Low; Katy J L Bell Journal: BMC Health Serv Res Date: 2018-06-20 Impact factor: 2.655
Authors: Deonna M Ackermann; Amelia K Smit; Monika Janda; Cathelijne H van Kemenade; Mbathio Dieng; Rachael L Morton; Robin M Turner; Anne E Cust; Les Irwig; Jolyn K Hersch; Pascale Guitera; H Peter Soyer; Victoria Mar; Robyn P M Saw; Donald Low; Cynthia Low; Dorothy Drabarek; David Espinoza; Jon Emery; Peter Murchie; John F Thompson; Richard A Scolyer; Anthony Azzi; Alister Lilleyman; Katy J L Bell Journal: Trials Date: 2021-05-04 Impact factor: 2.279
Authors: Jake R Thompson; Andrea L Smith; Serigne N Lo; Nadine A Kasparian; Robyn Pm Saw; Mbathio Dieng; Linda Seaman; Linda K Martin; Pascale Guitera; Donna Milne; Helen Schmid; Anne E Cust; Iris Bartula Journal: BMJ Open Date: 2022-03-03 Impact factor: 2.692
Authors: Yvonne L Luigjes-Huizer; Nina M Tauber; Gerry Humphris; Nadine A Kasparian; Wendy W T Lam; Sophie Lebel; Sébastien Simard; Allan Ben Smith; Robert Zachariae; Yati Afiyanti; Katy J L Bell; José A E Custers; Niek J de Wit; Peter L Fisher; Jacqueline Galica; Sheila N Garland; Charles W Helsper; Mette M Jeppesen; Jianlin Liu; Roxana Mititelu; Evelyn M Monninkhof; Lahiru Russell; Josée Savard; Anne E M Speckens; Sanne J van Helmondt; Sina Vatandoust; Nicholas Zdenkowski; Marije L van der Lee Journal: Psychooncology Date: 2022-04-07 Impact factor: 3.955
Authors: Caitlin R Semsarian; Tara Ma; Brooke Nickel; Richard A Scolyer; Peter M Ferguson; H Peter Soyer; Lisa Parker; Alexandra Barratt; John F Thompson; Katy J L Bell Journal: Br J Dermatol Date: 2022-04-07 Impact factor: 11.113
Authors: Katie J Lee; Brigid Betz-Stablein; Mitchell S Stark; Monika Janda; Aideen M McInerney-Leo; Liam J Caffery; Nicole Gillespie; Tatiane Yanes; H Peter Soyer Journal: Front Med (Lausanne) Date: 2022-01-17